Observes patients with returned multiple myeloma treated with equecabtagene autoleucel
Studies how people with returned or resistant myeloma fare on equecabtagene autoleucel.
Plain-language title generated from the registry record
Registry title: A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Peking University People's HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT06369935
- Record updated
- 17 April 2024
- Original description
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective dataRead full original descriptionShow less
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data
Inclusion: Adult patients with confirmed relapsed/refractory multiple myeloma; Based on clinical practice, the physician decided to administer equecabtagene autoleucel treatment; Voluntarily sign the informed consent form approved by the ethics committee.
Exclusion: Patients who are hypersensitive to the active ingredients of the product or any excipients (dimethyl sulfoxide, compound electrolyte injection, human albumin); The researcher believes that patients are unable to return for follow-up visits or that it is impossible to complete the study; Patients with expected survival less than 3 months.